Coronary restenosis

Holmes DR Jr, Leon MB, Moses JW, Popma JJ, Cutlip D, Fitzgerald PI, Brown C, Fischell T, Wong SC, Midei M, Snead D, Kuntz RE. Analysis of 1-year clinical outcomes in the SIRIUS trial a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation. 2004 Feb 10 109(5) 634-40. [Pg.83]

In a study by Zohlnhofer et al. [140], 56 AMI patients were assigned to receive G-CSF treatment after successful percutaneous coronary intervention. Those patients were compared with 58 patients assigned to receive a placebo. The G-CSF treatment did not influence infarct size, left ventricular function, or coronary restenosis, and G-CSF was not associated with adverse outcomes. [Pg.114]

Hemophilia A and B Pulmonary diseases Cystic fibrosis Peripheral vascular disease Coronary restenosis Cancer... [Pg.402]

In a pilot study after coronary angioplasty in 22 patients, sirolimus was given orally in a loading dose of 6 mg followed by 2 mg/day over 4 weeks. Sirolimus was withdrawn after an average of 15 days in 11 patients because of adverse effects, including hypertriglyceridemia (n — 3), leukopenia (n = 3), raised liver function tests, stomatitis, acne, flu-like symptoms, and physician preference (n — 1 each). The rate of coronary restenosis was 87%. Sirolimus did not benefit patients with recalcitrant stenosis and adverse effects were frequent (1069). [Pg.648]

Lau HK, Segev A, Hegele RA, et al. Thrombin-activatable fibrinolysis inhibitor (TAFI) a novel predictor of angiographic coronary restenosis, Thromb Haemost 2003 90(6) I 187-1 191. [Pg.27]

Balk EM, Lichtenstein AH, Chung M, Kupelnick B, Chew R Lau J. Effects of omega-3 fatty acids on coronary restenosis, intima-media thickness, and exercise tolerance a systematic review. Atherosclerosis 2006 184 237-246. [Pg.169]

Schnyder G, et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001 345(22) 1593-1600. [Pg.184]

Table 2 Oral agents to treat coronary restenosis and the trials conducted ...

In the past, several clinical studies with corticosteroids failed to demonstrate a significant reduction in coronary restenosis after percutaneous transluminal coronary angioplasty (35,36). However, as we mentioned previously, after balloon angioplasty, there were other mechanisms involved in the pathophysiology of coronary restenosis (such as acute wall recoil or chronic remodeling) that explained the negative results of those studies (35,36). [Pg.195]

Heldman AW, Cheng L, Jenkins GM, et al. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 2001 103( 18) 2289-2295. [Pg.263]

Kim W, Jeong MH, Cha KS, et al. Effect of anti-oxidant (carvedilol and probucol) loaded stents in a porcine coronary restenosis model. CircJ 2005 69(1) 101-106. [Pg.264]

Rensing BJ, Vos J, Smits PC, et al. Coronary restenosis elimination with a sirolimus eluting stent first European human experience with 6-month angiographic and intravascular ultrasonic follow-up. Eur Heart J 2001 22(22) 2125-2130. [Pg.264]

Bailey SR. Coronary restenosis a review of current insights and therapies. Catheter Cardiovasc Interv 2002 55(2) 265-271. [Pg.276]

I I Eccleston D, Topol EJ. Clinical trials of restenosis. In Feuerstein GZ, ed. Coronary Restenosis—From Genetics to Therapeutics. NewYbrk Marcel Dekker, Inc., 1997 333-370. [Pg.276]

Verin V Popowski X de Bruyne B, et al. Endoluminal beta-radiation therapy for the prevention of coronary restenosis after balloon angioplasty, N Engl J Med 2001 344(4) 243-249. [Pg.286]

Baieri V Baumgartner S, Pollinger B, et al. Three-year clinical follow-up after strontium/yttrium beta-irradiation for the treatment of in-stent coronary restenosis. Am J Cardiol 2005 96 1399-1403. [Pg.286]

Kent KN, Williams DO, Cassagneau B, et al, Double-blind, controlled trial of the effect of angiopeptin on coronary restenosis following coronary angioplasty. Circulation 1993 88(suppl l) 5063. [Pg.313]

Eriksen UH, Amtorp O, Bagger JR et al. Continuous angiopeptin infusion reduces coronary restenosis following balloon angioplasty. Circulation 1993 88(suppl l) 594. [Pg.313]

Muller DM. The role of proto-oncogenes in coronary restenosis. Pro Cardiovasc Ids 1997 40(2) I 17-128. [Pg.379]

Kipshidze NN, Iversen B Kim HS, etal. Advanced c-myc anti-sense (AVI-4126)-eluting phosphorylcholine-coated stent implantation is associated with complete vascular healing and reduced neointimal formation in the porcine coronary restenosis model. Catheter Cardiovasc Interv 2004 61 (4) 518-527. [Pg.379]

Kipshidze NN, Porter TR, Dangas G, et al. Systemic targeted delivery of antisense with perflourobutane gas microbubble carrier reduced neointimal formation in the porcine coronary restenosis model, Cardiovasc Radiat Med 2003 4(3) 152-159. [Pg.380]

PhotoPoint (AX/ravanf) MV0633 Vulnerable plaque and coronary restenosis ... [Pg.383]

Rabbit muscle 27 HA is a major constituent in the pathological matrix that occludes the artery in coronary restenosis. [Pg.793]

Coronary Restenosis From Genetics to Therapeutics, edited by Giora Z. Feuerstein... [Pg.250]

Strauss BH, Lau HK, Bowman KA et aL Plasma urokinase antigen and plasminogen activator inhibitor-1 antigen levels predict angiographic coronary restenosis. Circulation 1999 100 1616-1622... [Pg.154]

Schnyder, G., Roffi, M., Pin, R., Flammer, Y., Lange, H., Eberli, F.R., Meier, B., Turi, Z.G., and Hess, O.M., 2001. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. New England Journal of Medicine. 345 1593-1600. [Pg.85]

J. Mehilli, R.A. Byrne, A. Wieczorek, R. lijima, S. Schulz, O. Bruskina, J. Pache, R. Wessely, A. Schomig, and A. Kastrati, Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis, Eur. Heart 29 (16), 1975-1982, 2008. [Pg.435]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...